Journal article
Filgotinib for the treatment of rheumatoid arthritis
- Abstract:
-
Introduction: Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy. Being proteins, they are administered parenterally. The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA pathogenesis. Areas covered: Several JAK inhibitors have been developed with differing selectivity for the four JAK enzymes with...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 177.9KB)
-
(Accepted manuscript, jpeg, 32.3KB)
-
(Accepted manuscript, pdf, 16.1KB)
-
(Accepted manuscript, pdf, 18.9KB)
-
- Publisher copy:
- 10.1080/13543784.2017.1372422
Authors
Bibliographic Details
- Publisher:
- Taylor and Francis Publisher's website
- Journal:
- Expert Opinion on Investigational Drugs Journal website
- Volume:
- 26
- Issue:
- 10
- Pages:
- 1181-1187
- Publication date:
- 2017-08-24
- Acceptance date:
- 2017-08-24
- DOI:
- EISSN:
-
1744-7658
- ISSN:
-
1354-3784
- Source identifiers:
-
725767
Item Description
- Pubs id:
-
pubs:725767
- UUID:
-
uuid:3e4afb6e-5cb2-4c28-840d-154bb0bf7cbc
- Local pid:
- pubs:725767
- Deposit date:
- 2017-09-07
Terms of use
- Copyright date:
- 2017
- Notes:
- This is the author accepted manuscript following peer review version of the article. The final version is available online from Taylor and Francis at: 10.1080/13543784.2017.1372422
If you are the owner of this record, you can report an update to it here: Report update to this record